Blueprint Medicines Past Earnings Performance
Past criteria checks 0/6
Blueprint Medicines's earnings have been declining at an average annual rate of -21%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 10.4% per year.
Key information
-21.0%
Earnings growth rate
-14.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 10.4% |
Return on equity | -388.2% |
Net Margin | -203.3% |
Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)
Apr 05Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Feb 20Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 08Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%
Dec 18Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Nov 07Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
Sep 15Blueprint to seek label expansion for systemic mastocytosis therapy after trial win
Aug 17Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance
Aug 02Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront
Jun 30Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook
Feb 17Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation
Nov 10Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)
Oct 15Revenue & Expenses BreakdownBeta
How Blueprint Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 249 | -507 | 295 | 428 |
30 Sep 23 | 216 | -555 | 280 | 448 |
30 Jun 23 | 226 | -554 | 265 | 468 |
31 Mar 23 | 205 | -581 | 251 | 486 |
31 Dec 22 | 204 | -558 | 237 | 477 |
30 Sep 22 | 272 | -718 | 228 | 716 |
30 Jun 22 | 230 | -702 | 220 | 673 |
31 Mar 22 | 221 | -650 | 210 | 624 |
31 Dec 21 | 180 | -644 | 195 | 601 |
30 Sep 21 | 107 | -411 | 184 | 322 |
30 Jun 21 | 828 | 340 | 171 | 487 |
31 Mar 21 | 809 | 325 | 164 | 407 |
31 Dec 20 | 794 | 314 | 158 | 327 |
30 Sep 20 | 811 | 333 | 147 | 249 |
30 Jun 20 | 75 | -395 | 136 | 0 |
31 Mar 20 | 72 | -371 | 115 | 0 |
31 Dec 19 | 67 | -348 | 96 | 331 |
30 Sep 19 | 16 | -362 | 78 | 0 |
30 Jun 19 | 8 | -340 | 64 | 0 |
31 Mar 19 | 44 | -267 | 55 | 0 |
31 Dec 18 | 45 | -237 | 48 | 0 |
30 Sep 18 | 45 | -205 | 42 | 0 |
30 Jun 18 | 52 | -170 | 38 | 0 |
31 Mar 18 | 17 | -177 | 32 | 0 |
31 Dec 17 | 21 | -148 | 28 | 0 |
30 Sep 17 | 27 | -120 | 25 | 0 |
30 Jun 17 | 26 | -99 | 22 | 0 |
31 Mar 17 | 27 | -85 | 20 | 0 |
31 Dec 16 | 28 | -72 | 19 | 0 |
30 Sep 16 | 25 | -67 | 18 | 0 |
30 Jun 16 | 22 | -63 | 17 | 0 |
31 Mar 16 | 18 | -58 | 16 | 0 |
31 Dec 15 | 11 | -56 | 14 | 0 |
30 Sep 15 | 7 | -57 | 14 | 0 |
30 Jun 15 | 3 | -56 | 11 | 0 |
31 Mar 15 | 1 | -52 | 9 | 0 |
31 Dec 14 | 0 | -46 | 8 | 0 |
Quality Earnings: BPMC is currently unprofitable.
Growing Profit Margin: BPMC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BPMC is unprofitable, and losses have increased over the past 5 years at a rate of 21% per year.
Accelerating Growth: Unable to compare BPMC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BPMC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: BPMC has a negative Return on Equity (-388.17%), as it is currently unprofitable.